Roberta Fusari
Research Subjects
Roberta Fusari has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Damiano Abeni
Clinical Epidemiology Unit, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, 00167 Rome, Italy
2 shared publications - Luca Fania
Skin Cancer Center, Istituto Dermopatico dell’Immacolata-IRCCS, 00167 Rome, Italy
2 shared publications - Anna Dattolo
Laboratory of Experimental Immunology, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, 00167 Rome, Italy
1 shared publication - Davide Ciccone
Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, 00167 Rome, Italy
1 shared publication - Francesca Sampogna
Clinical Epidemiology Unit, Istituto Dermopatico Dell’Immacolata IDI-IRCCS, Rome, Italy
1 shared publication Giorgia Cordella
Clinical Psychology Unit, IDI-IRCCS, Via dei Monti di Creta, 104, IT-00167 Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 27 January 2023
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 103, adv00856
Similar Levels of Disease Severity Correspond to a Greater Burden of Illness in Women Compared with Men with Hidradenitis Suppurativa
Is missing (Short communication)
- 27 January 2023
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 103, adv00856
Open AccessSimilar Levels of Disease Severity Correspond to a Greater Burden of Illness in Women Compared with Men with Hidradenitis Suppurativa
Is missing (Short communication)
- Open Access
- 18 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3648
Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa
Background. Pain is one of the main aspects of hidradenitis suppurativa that strongly affects the quality of life of patients. We explored the relationship between pain and clinical severity as well as its role in defining the health status in patients with HS. Methods. Pain was defined by three measures: (a) question 1 (“my skin hurts”) of the Skindex-17; (b) Bodily Pain (BP) scale of the SF-36; and (c) Visual Analog Scale (VAS). Clinical severity of HS was assessed by the Hurley staging, the Sartorius HS Score, and the International HS Severity Score System. Results. The study population included 341 HS patients with complete data for the VAS pain, 316 for question 1 of the Skindex-17, and 294 for BP. Clinical severity was positively associated with pain. This result was observed for all three severity scores and all three pain evaluation methods. In addition, the number of fistulae, abscesses, and nodules were significantly associated with the three severity measures of pain, while the association with scars was not observed for question 1 of the Skindex-17 and BP. Conclusions. Pain may be a good proxy of clinical severity and efficacy of a treatment in HS and therefore a crucial hallmark of patients’ health status.
- 18 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3648
Open AccessPain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa
Background. Pain is one of the main aspects of hidradenitis suppurativa that strongly affects the quality of life of patients. We explored the relationship between pain and clinical severity as well as its role in defining the health status in patients with HS. Methods. Pain was defined by three measures: (a) question 1 (“my skin hurts”) of the Skindex-17; (b) Bodily Pain (BP) scale of the SF-36; and (c) Visual Analog Scale (VAS). Clinical severity of HS was assessed by the Hurley staging, the Sartorius HS Score, and the International HS Severity Score System. Results. The study population included 341 HS patients with complete data for the VAS pain, 316 for question 1 of the Skindex-17, and 294 for BP. Clinical severity was positively associated with pain. This result was observed for all three severity scores and all three pain evaluation methods. In addition, the number of fistulae, abscesses, and nodules were significantly associated with the three severity measures of pain, while the association with scars was not observed for question 1 of the Skindex-17 and BP. Conclusions. Pain may be a good proxy of clinical severity and efficacy of a treatment in HS and therefore a crucial hallmark of patients’ health status.